變應原特異性免疫治療(SIT)是目前已知的唯一能改變變態反應性疾病患者對變應原免疫的類型，并有可能治愈變態反應性疾病的方法。通常是通過反復多次皮下注射，即皮下免疫治療(SCIT)，誘導患者對變應原的耐受，但因其不良反應較大，并有可能引起過敏性休克等原因而使其應用受到限制。近來通過舌下含服的方法進行免疫治療，即舌下免疫治療(SLIT)，引起了臨床上廣泛的興趣。與SCIT相比，SLIT完全由患者自己使用藥物，因此更方便，臨床研究也證實這種方法更安全，也更有效。而且與藥物治療相比，SLIT可以顯著降低臨床費用，減輕患者和社會的負擔。但是SLIT誘導免疫耐受的確切機制目前仍不清楚。
Objective To investigate the effects of FasL gene-modified dendritic cell (DC) on the airway inflammation in mice sensitized/challenged by house dust mite (HDM) allergen.Methods FasL gene-modified DC (FasL-DC) and control DC (nontransfection DC) were administrated into HDM sensitized and challenged mice by intratracheal injection respectively，then HDM sensitized and challenged mice were sacreificed two days later.Total and differentiation cell counts and levels of interleukin-4（IL-4），IL-5 and interferon-γ(IFN-?) in bronchoalveolar lavage fluid (BALF) were detected and lung histological features were observed.Results After administration of FasL-DC，lung allergic inflammation was ameliorated while total cell counts，the percentage of eosinophil ,the levels of IL-4 and IL-5 in BALF decreased and the level of IFN-? in BALF increased.Conclusion Administrating FasL-DC into HDM sensitized/challenged mice can inhibit Th2 cells activation and ameliorate airway allergic inflammation.
【摘要】 目的 研究Monaco治療計劃系統中不同參數設置對容積旋轉調強放射治療(VMAT)計劃質量的影響，得出更合理的治療計劃參數設置以提高VMAT治療質量。 方法 2010年1-5月間治療3例患者，為食管癌、宮頸癌和鼻咽癌各1例，分別設置不同的計劃參數進行容積旋轉調強計劃優化，通過多種評估指標比較各VMAT計劃質量的差異，得出臨床所需的MSC、MSS、SSF、Sm、MMS和MDR共6個治療計劃參數對VMAT治療質量的影響。 結果 MSC、MSS和SSF的3個參數對VMAT治療質量不產生影響，有影響的Sm、MMS和MDR參數中，隨著Sm和MMS值的增大，VMAT計劃的劑量分布逐漸變差，但控制點數、機器跳數和照射時間均逐漸減小；隨著MDR值增大，VMAT治療的劑量分布先逐漸變差后不變，控制點數和機器跳數均是先增大后不變，而照射時間是先減小后不變。 結論 Sm、MMS和MDR 3個參數對VMAT計劃質量有較大影響，對不同的患者，設置合適的Sm、MMS和MDR值對提高計劃質量非常重要。【Abstract】 Objective To investigate the impacts of parameter settings on the quality of plans for the volumetric modulated arc therapy (VMAT) with Monaco treatment planning system. Methods Three patients who underwent VMAT from January to May 2010 were selected. The planning optimizations were processed by setting different planning parameters, including MSC, MSS, SSF, Sm, MMS and MDR, respectively. Then the quality of each plan with a certain set of parameters was evaluated by various evaluation indexes. The differences of quality among different plans were analyzed by comparing these indexes. Results There was no influence on the quality of VMAT planning for the parameter MSC, MSS and SSF to be set with different values. However, the other three parameters, MSC, MSS and SSF , affected the quality of VMAT planning with different values. Along with the aggrandizement of Sm and MMS value, the dose distribution of VMAT plans gradually became bad, while the number of control points, machine monitor units and irradiation time were gradually reduced. And along with the aggrandizement of MDR value, the dose distribution of VMAT plans became bad gradually until a constant state was reached, and both the number of control points and machine monitor units increased at first and then kept constant, while irradiation time decreased at first and then kept constant. Conclusion The selections of parameter Sm, MMS and MDR impact the quality of VMAT planning greatly. It is very important to set the suitable value of Sm, MMS and MDR to get the best planning quality for patients with different complexity.
【摘要】 目的 研究千伏級錐形束CT（kV-cone beam CT，kV-CBCT）影像用于鼻咽癌調強放射治療計劃劑量計算的可行性和精確度。 方法 2010年7-9月7例鼻咽癌患者 ，獲取每例患者的第1天放射治療時的kV-CBCT影像。用CIRS062密度模體和患者自身特定區域亨氏單位值（hounsfield unit，HU）映射的兩種方法重新刻度亨氏單位值-相對電子密度（HU-RED）表，分別進行劑量計算，并與在傳統扇形束CT（FBCT）影像上的原放射治療計劃結果進行對比，包括輻射劑量分布、靶區和危及器官的劑量體積直方圖（DVH）。 結果 kV-CBCT影像的治療計劃和原治療計劃在劑量分布和DVH上有較好的一致性。在劑量分布的比較上采用了γ分析（2%/2 mm標準的通過率），用基于模體的HU-RED表得到的治療計劃與原治療計劃對比，在經過等中心冠狀面、矢狀面和橫斷面的通過率分別為92.7%±3.5%、95.1%±3.1%和95.7%±3.4%，用基于患者的HU-RED表得到治療計劃與原治療計劃對比的通過率分別為94.8%±2.7%、96.6%±2.9%和97.4%±2.7%。DVH的統計數據表明，兩種方法得到的kV-CBCT治療計劃和原治療計劃相比較，靶區和危及器官劑量偏差大多數在2%以內。有1例因在橫斷面發生了明顯的旋轉誤差，導致在橫斷面的通過率很低，DVH統計數據較原計劃偏差較大。 結論 kV-CBCT影像可以用來做輻射劑量計算，基于患者自身影像生成的HU-RED表的治療計劃較原治療計劃有更高的符合度。【Abstract】 Objective To evaluate the feasibility and accuracy of dose calculation based on cone beam CT (CBCT) data sets for intensity modulated radiation therapy (IMRT) planning of nasopharyngeal cancer (NPC). Methods Seven NPC patients were selected. The kV-CBCT images for each patient were acquired on the first treatment day. Two correction strategies were used to generate the cone beam HU value vs relative electron density calibration tables which named CIRS062 phantom based HU-RED tables and patient specific HU-RED tables respectively for dose calculation. The dose distributions and dose volume histograms (DVHs) of the target and organs at risk (OAR) based on kV-CBCT images were compared to the plans based on the fan-beam CT (FBCT). Results The DVH and dose distribution comparison between plans based on the FBCT and those on the CBCT showed good agreements. The γ analysis with a criterion of 2 mm/2% was used for the comparison of dose distribution at the coronal plane, sagital plane and cross plane through the isocenter point. The passing rate from phantom based HU-RED tables were (92.7±3.5) %, (95.1±3.1) %, and (95.7±3.4)%, respectively. The passing rates from the patient specific HU-RED tables were (94.8±2.7) %, (96.6±2.9) %, and (97.4±2.7) %, respectively. The dose difference between plans based on CBCT and those based on FBCT was within 2% at most patients by analyzing DVH based parameters. Only one patient who had significant rotation setup error resulted in the low passing rate and disagreement in DVH. Conclusion The CBCT images can be used to do dose calculation in IMRT planning of NPC. The differences between plans based on HU-RED tables generated by specific patient and the original plans are less than those between plans based on CIRS062 phantom based HU-RED tables and the original plans.
ObjectiveTo understand the trend and problems of asthma treatment in different levels of hospitals in Chongqing, and to provide objective basis for more refined and standardized asthma management. MethodsThe outpatient and inpatient asthma diagnosis and treatment data of four hospitals of different grades in Chongqing from 2017 to 2021 were extracted by medical big data capture platform, and the trend of outpatient and prescription changes was analyzed retrospectively according to natural year. ResultsThere were 19514 outpatients asthma visits in the four hospitals, of whom 11816 (60.6%) were female. There were 1875 hospitalizations, of which 1117 (59.6%) were female. ① Changes of asthma visit mode: From 2017 to 2019, the number of outpatient asthma visits and the proportion of asthma in the total outpatient volume increased, decreased significantly in 2021, and basically recovered to the level of 2019 in 2022. Asthma hospitalizations in tertiary hospitals showed a decreasing trend, while those in secondary hospitals increased significantly. The proportion of asthma patients who chose outpatient treatment in the four hospitals increased year by year, among which the increase was more significant in non-tertiary teaching hospitals, and the proportion of asthma acute attack in outpatient and inpatient treatment increased. ② Changes of medication pattern: The rate of inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) prescription in outpatient department increased year by year, the highest was 48.6%, but the rate of short-acting β2-agonists (SABA) prescription also increased year by year, especially in secondary hospitals, the rate of SABA prescription in secondary hospitals reached 39.7%. The proportion of hospitalized asthma patients treated with inhaled corticosteroids (85.1%) was higher than that of intravenous corticosteroids (50.9%), and the proportion of intravenous theophylline prescription was as high as 91.7%, while the proportion of nebulized SABA prescription was 71.4%. ConclusionsThe trend of asthma diagnosis and treatment is that the number of outpatients and the use of ICS/LABA is gradually increasing, while the number of inpatients is decreasing. However, there is still a large gap in the proportion of asthma maintenance medication used in different levels of hospitals, so it is necessary to continuously promote standardized diagnosis and treatment management of asthma in hospitals at all levels, especially primary hospitals.